The primary goal of this Phase I STTR proposal is to develop a prototype of a rapid molecular diagnostics test to improve prediction of the antibiotic resistance of uropathogenic. Escherichia coli by determining their clonal identity (clonotype). The clonotype determination will be done by detection of the presence/absence of a limited number (d10) of single nucleotide polymorphisms (SNPs) that will be selected from 8 genetic loci used for the clonal typing of E. coli - seven loci from the standard multi-locus sequence typing (MLST) scheme for E. coli and fast-evolving gene for the type 1 fimbrial adhesin, fimH. The SNPs binary interrogation could be performed in either thermocycler or isothermal DNA amplification protocols using a simple single-plex configuration adapted to the standard 8-/12-tube PCR strips and common instrumentation platforms. These tests will be designed to perform in near-patient settings such as clinical laboratories in emergency rooms, urgent care clinics and/or hospitals. The test will be done using patients' urine in a cost-effective and timely manner (<30 min), with the goal to improve the empirical (pre-antibiogram) choice of antibiotic treatment, reducing potential 'drug-bug' mismatch and overuse of last-line broad-spectrum antimicrobials. To achieve the goals, we will determine MLST/fimH and antibiogram profiles of a comprehensive number of clinical isolates and establish the association between resistance to commonly used antibiotics and the clonal identity of pathogens. Phylogenetically-unlinked (homoplasic) SNPs that are distributed across the clonotypes in a relatively random and even fashion will be identified. Alternate combinations of 6 to 10 SNPs will be analyzed for the ability to discriminate up to 100 of the most critical (size- and resistance-wise) clonotypes of E. coli. Oligonucleotide primers capable of robust interrogation of the SNP combinations will be designed and validated for different amplification protocols. The proposed studies will be performed as collaboration between ID Genomics, Inc, the University of Washington's start-up company specializing in sequence-based typing of microbial pathogens, and the University of Washington, Seattle, laboratory of Evgeni Sokurenko (the lead PI).

Public Health Relevance

We are proposing to develop a molecular diagnostic technology for a test kit to predict antibiotic resistance of bacteria causing urinary tract infectons in humans, based on the genetic family (clonal type) they belong to. The kits will be designed for use in emergency or urgent care clinics and hospitals to perform directly on urine and in a timely (<30 min) manner.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41AI116114-01
Application #
8838367
Study Section
Special Emphasis Panel (ZRG1-IMST-J (15))
Program Officer
Ritchie, Alec
Project Start
2014-12-15
Project End
2015-11-30
Budget Start
2014-12-15
Budget End
2015-11-30
Support Year
1
Fiscal Year
2015
Total Cost
$214,436
Indirect Cost
Name
Idgenomics, Inc.
Department
Type
DUNS #
078779585
City
Seattle
State
WA
Country
United States
Zip Code
98105